Fate Therapeutics

🇺🇸United States
Ownership
-
Employees
220
Market Cap
$408.8M
Website

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

First Posted Date
2020-01-29
Last Posted Date
2023-10-26
Lead Sponsor
Fate Therapeutics
Target Recruit Count
98
Registration Number
NCT04245722
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

First Posted Date
2019-09-26
Last Posted Date
2023-09-21
Lead Sponsor
Fate Therapeutics
Target Recruit Count
20
Registration Number
NCT04106167
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

UCSD Moores Cancer Center, San Diego, California, United States

🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 1 locations

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

First Posted Date
2019-09-18
Last Posted Date
2022-08-29
Lead Sponsor
Fate Therapeutics
Target Recruit Count
2
Registration Number
NCT04093622
Locations
🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

and more 2 locations

FT516 in Subjects With Advanced Hematologic Malignancies

First Posted Date
2019-07-17
Last Posted Date
2023-10-26
Lead Sponsor
Fate Therapeutics
Target Recruit Count
72
Registration Number
NCT04023071
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

and more 4 locations

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

First Posted Date
2019-02-15
Last Posted Date
2023-05-01
Lead Sponsor
Fate Therapeutics
Target Recruit Count
37
Registration Number
NCT03841110
Locations
🇺🇸

Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States

🇺🇸

University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

First Posted Date
2017-10-24
Last Posted Date
2021-11-22
Lead Sponsor
Fate Therapeutics
Target Recruit Count
44
Registration Number
NCT03319459
Locations
🇺🇸

UCSD Moores Cancer Center, San Diego, California, United States

🇺🇸

The Ohio State University James Cancer Hospital, Columbus, Ohio, United States

🇺🇸

Baylor Scott & White Research Institute, Dallas, Texas, United States

and more 1 locations

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

First Posted Date
2016-04-19
Last Posted Date
2023-02-08
Lead Sponsor
Fate Therapeutics
Target Recruit Count
96
Registration Number
NCT02743351
Locations
🇺🇸

The Ohio State University, Columbus, Ohio, United States

🇺🇸

Indiana Blood and Marrow Transplant, Indianapolis, Indiana, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 12 locations

A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2015-02-03
Last Posted Date
2018-10-10
Lead Sponsor
Fate Therapeutics
Target Recruit Count
1
Registration Number
NCT02354443
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

Phase 1
Terminated
Conditions
First Posted Date
2015-02-03
Last Posted Date
2018-10-10
Lead Sponsor
Fate Therapeutics
Target Recruit Count
3
Registration Number
NCT02354417
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

City of Hope, Duarte, California, United States

The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

First Posted Date
2012-06-25
Last Posted Date
2021-11-30
Lead Sponsor
Fate Therapeutics
Target Recruit Count
62
Registration Number
NCT01627314
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute- Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath